Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 3/2004

01-08-2004

A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: A Southwest Oncology Group Study

Authors: Robert P. Whitehead, Jacqueline K. Benedetti, James L. Abbruzzese, Bach Ardalan, J. Wendall Goodwin, Stanley P. Balcerzak, Wolfram E. Samlowski, Heinz-Josef Lenz, John S. Macdonald

Published in: Investigational New Drugs | Issue 3/2004

Login to get access
Metadata
Title
A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: A Southwest Oncology Group Study
Authors
Robert P. Whitehead
Jacqueline K. Benedetti
James L. Abbruzzese
Bach Ardalan
J. Wendall Goodwin
Stanley P. Balcerzak
Wolfram E. Samlowski
Heinz-Josef Lenz
John S. Macdonald
Publication date
01-08-2004
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 3/2004
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/B:DRUG.0000026261.76197.54

Other articles of this Issue 3/2004

Investigational New Drugs 3/2004 Go to the issue

OriginalPaper

Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: A preclinical study

OriginalPaper

Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma

OriginalPaper

9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium

OriginalPaper

Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors

OriginalPaper

Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer

OriginalPaper

Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits